KIROMIC BIOPHARMA INC (KRBP) Stock Price & Overview
NASDAQ:KRBP • US4976342042
The current stock price of KRBP is 1.45 USD. Today KRBP is down by -8.23%. In the past month the price decreased by -38.56%. In the past year, price decreased by -86.7%.
KRBP Key Statistics
- Market Cap
- 1.706M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -47.46
- Dividend Yield
- N/A
KRBP Stock Performance
KRBP Stock Chart
KRBP Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to KRBP. When comparing the yearly performance of all stocks, KRBP is a bad performer in the overall market: 97.68% of all stocks are doing better.
KRBP Earnings
KRBP Forecast & Estimates
KRBP Groups
Sector & Classification
KRBP Financial Highlights
Over the last trailing twelve months KRBP reported a non-GAAP Earnings per Share(EPS) of -47.46. The EPS increased by 24.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
KRBP Ownership
KRBP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16 | 417.437B | ||
| AMGN | AMGEN INC | 16.31 | 204.229B | ||
| GILD | GILEAD SCIENCES INC | 16.27 | 183.894B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.6 | 121.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 83.255B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.84 | 43.24B | ||
| INSM | INSMED INC | N/A | 31.965B | ||
| NTRA | NATERA INC | N/A | 28.775B | ||
| BIIB | BIOGEN INC | 12.36 | 27.876B | ||
| MRNA | MODERNA INC | N/A | 22.581B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.24 | 21.486B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.053B | ||
| EXAS | EXACT SCIENCES CORP | 308.82 | 19.749B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KRBP
Company Profile
Kiromic Biopharma, Inc. operates as a clinical-stage biotherapeutics company. The company is headquartered in Houston, Texas and currently employs 31 full-time employees. The company went IPO on 2020-10-16. The firm is engaged in developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The Procel, Isocel, and Deltacel product platform candidates consist of allogeneic cell therapy candidates that are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs targeting PD-L1. Its Isocel product candidate consists of engineered GDTs targeting Mesothelin Isoform 2 positive tumors (Iso-Meso). Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. Its Allogenic Lead Exogenous Isoforms (ALEXIS)-PRO-1 trial candidate is its allogeneic GDT therapy product targeting PD-L1. Its ALEXIS-ISO-1 trial candidate is its allogenic GDT therapy product targeting an isoform of Mesothelin that is present in tumor cells, namely Isomeso.
Company Info
KIROMIC BIOPHARMA INC
7707 Fannin St., Suite 140
Houston TEXAS 77054 US
CEO: Maurizio Chiriva-Internati
Employees: 31
Phone: 18329684888.0
KIROMIC BIOPHARMA INC / KRBP FAQ
Can you describe the business of KIROMIC BIOPHARMA INC?
Kiromic Biopharma, Inc. operates as a clinical-stage biotherapeutics company. The company is headquartered in Houston, Texas and currently employs 31 full-time employees. The company went IPO on 2020-10-16. The firm is engaged in developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The Procel, Isocel, and Deltacel product platform candidates consist of allogeneic cell therapy candidates that are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs targeting PD-L1. Its Isocel product candidate consists of engineered GDTs targeting Mesothelin Isoform 2 positive tumors (Iso-Meso). Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. Its Allogenic Lead Exogenous Isoforms (ALEXIS)-PRO-1 trial candidate is its allogeneic GDT therapy product targeting PD-L1. Its ALEXIS-ISO-1 trial candidate is its allogenic GDT therapy product targeting an isoform of Mesothelin that is present in tumor cells, namely Isomeso.
Can you provide the latest stock price for KIROMIC BIOPHARMA INC?
The current stock price of KRBP is 1.45 USD. The price decreased by -8.23% in the last trading session.
What is the dividend status of KIROMIC BIOPHARMA INC?
KRBP does not pay a dividend.
How is the ChartMill rating for KIROMIC BIOPHARMA INC?
KRBP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the employee count for KRBP stock?
KIROMIC BIOPHARMA INC (KRBP) currently has 31 employees.
When does KIROMIC BIOPHARMA INC (KRBP) report earnings?
KIROMIC BIOPHARMA INC (KRBP) will report earnings on 2023-11-13, after the market close.